

2. **(Amended)** The RNA molecule of Claim 1, which is replication-competent in the target cell.
3. **(Amended)** The RNA molecule of Claim 1, wherein in the virus genome parts of its coding sequence have been replaced by the at least one foreign gene.
4. **(Amended)** The RNA molecule of Claim 2, wherein in the virus genome the sequences of its capsid proteins VP1-VP4 have been replaced by the at least one foreign gene.
5. **(Amended)** The RNA molecule of Claim 2, wherein in the virus genome the sequences of its protease 2A and/or 3C have been modified such that there is no cytotoxicity for the target cell.
6. **(Amended)** The RNA molecule of Claim 2, wherein in the virus genome the sequences of its helicase 2C have been replaced by the at least one foreign gene.
7. **(Amended)** The RNA molecule of Claim 2, wherein in the virus genome the sequences of its protein 2B have been replaced by the at least one foreign gene.
9. **(Amended)** A recombinant, infectious virion which is derived from Coxsackie Virus group B, preferably serotype B3, and whose genome comprises the RNA molecule of Claim 1.
10. **(Amended)** The virion of Claim 9, which corresponds in its structural proteins to a Coxsackie virus group B, preferably serotype B3.
12. **(Amended)** A vector plasmid having at least one DNA sequence which codes for the RNA molecule of Claim 1, and having a promoter located in front of the DNA sequence.
13. **(Amended)** A helper construct for complementing the coding sequences replaced in the RNA molecule of Claim 1.
14. **(Amended)** The helper construct of Claim 13, which is a helper plasmid which codes for at least one of the replaced sequences in a translatable manner.
15. **(Amended)** The helper construct of Claim 13, which is a viral vector which codes for at least one of the replaced sequences in a translatable manner.
16. **(Amended)** The helper construct of Claim 13, which is a helper cell which has been transfected stably with helper DNA coding for at least one of the replaced sequences.
21. **(Amended)** A kit, comprising the vector plasmid of Claim 12 and the helper construct of Claim 13.
22. **(Amended)** A DNA molecule having at least one sequence section coding for the RNA molecule of Claim 1.

25. (Amended) A therapeutic composition comprising the RNA molecule of Claim 1.
27. (Amended) A therapeutic composition with the virion of claim 9.
28. (Amended) A DNA construct which codes for the RNA molecule of Claim 1 and which persists and transcribes in a target cell but preferably does not replicate in the latter.
29. (Amended) A recombinant virus, preferably adeno- or retrovirus, which codes for the RNA molecule of Claim 1 and, after infection, expresses it in a target cell, leading to a cytoplasmic replicon which is produced continuously.

**Please, add new Claims:**

33. (New) The RNA molecule of claim 2, wherein in the virus genome the sequences of its protease 2A and/or 3C have been replaced by the at least one foreign gene.
34. (New) A recombinant, infectious virion which is derived from Coxsackie Virus group B, preferably serotype B3, and whose genome comprises the RNA molecule of Claim 2.
35. (New) A vector plasmid having at least one DNA sequence which codes for the RNA molecule of Claim 2, and having a promoter located in front of the DNA sequence.
36. (New) A helper construct for complementing the coding sequences replaced in the RNA molecule of Claim 2.
37. (New) A DNA molecule having at least one sequence section coding for the RNA molecule of Claim 2.
38. (New) A therapeutic composition comprising the RNA molecule of Claim 2.
39. (New) A DNA construct which codes for the RNA molecule of Claim 2 and which persists and transcribes in a target cell but preferably does not replicate in the latter.
40. (New) A recombinant virus, preferably adeno- or retrovirus, which codes for the RNA molecule of Claim 2 and, after infection, expresses it in a target cell, leading to a cytoplasmic replicon which is produced continuously.

**REMARKS**

An Abstract has been added to the Specification. Claims 8, 11, 17, 18, 19, 20, 24, 31, and 32 have been cancelled without prejudice. Claims 2-7, 9, 10, 12-16, 21, 22, 25, 27, 28, and 29 have been amended to more precisely claim the invention according to conventional practice before the United States Patent and Trademark Office. New Claims 33 – 40 have been added. Support for new Claims 33 –40 can be found in original Claims. As a result Claims 1-7, 9, 10, 12-16, 21, 22, 23, 25-30, and 33 - 40 are presented for examination. No new matter is being